September 14, 2017
Novartis’s adalimumab offers alternative for patients with immunological diseases
Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
September 13, 2017
Biocartis, Genomic Health bring together their Oncotype DX breast recurrence score test and Idylla platform
Biocartis and Genomic Health have entered a deal to develop an IVD version of the Oncotype DX Breast Recurrence Score…
September 12, 2017
GSK progresses regulatory filings for treating COPD with mepolizumabthis in 2017
GlaxoSmithKline has published full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD). For people living…
September 12, 2017
HanAll Biopharma, Harbour BioMed team up to make and sell dry eye and other inflammatory diseases products
HanAll Biopharma and Harbour BioMed on Tuesday announced agreeing to produce and sell HanAll’s two novel biologics, in Greater China, including Hong Kong, Macau and Taiwan,…
September 12, 2017
Cardiome Pharmato to sell Basilea Pharmaceutica’s antibiotic in Nordic Europe and Israel
Basilea Pharmaceutica’s Basilea Pharmaceutica International Ltd. has entered into a distribution agreement with Cardiome Pharma Corp. for Basilea’s antibiotic Zevtera/Mabelio (ceftobiprole) in Europe (excluding Nordic countries) and Israel.
September 12, 2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
September 12, 2017
TiGenix CEO welcomes two new team members in US
Belgian biopharmaceutical stem cells focused company TiGenix NV has made two senior appointments to reinforce its U.S. operations, who will both…
September 11, 2017
Piramal Pharma Solutions name chief operating officer
Piramal Pharma Solutions (PPS), part of Piramal Enterprises Limited, has appointed John Fowler as its Chief Operating Officer last week. Fowler…
September 11, 2017
Santhera enrolls first n Duchenne Muscular Dystrophy patients in Raxone study
Santhera Pharmaceuticals has enrolled first DMD patients with respiratory function decline not taking glucocorticoids into UK’s Early Access to Medicines…
September 11, 2017
Sanofi, Regeneron’s asthma study meets two primary endpoints
The pivotal Phase 3 Libery ASthma Quest study of dupilumab in a broad population of patients with uncontrolled, persistent asthma…